BIOMAT Database Logo BIOMAT Database Logo

[In vitro antituberculous activity of lividomycin]. 1972

F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura

UI MeSH Term Description Entries
D007612 Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Kanamycin A,Kanamycin Sulfate,Kantrex
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002207 Capreomycin Cyclic peptide antibiotic similar to VIOMYCIN. It is produced by Streptomyces capreolus. Capreomycin Sulfate,Capastat,Capromycin
D004096 Dihydrostreptomycin Sulfate A semi-synthetic aminoglycoside antibiotic that is used in the treatment of TUBERCULOSIS. Dihydrostreptomycin,Citrocil,Sulfate, Dihydrostreptomycin
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D000636 Aminosalicylic Acids A group of 2-hydroxybenzoic acids that can be substituted by amino groups at any of the 3-, 4-, 5-, or 6-positions. Acids, Aminosalicylic
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D014756 Viomycin A strongly basic peptide, antibiotic complex from several strains of Streptomyces. It is allergenic and toxic to kidneys and the labyrinth. Viomycin is used in tuberculosis as several different salts and in combination with other agents. Florimycin,Tuberactinomycin B,Celiomycin,Vinactane,Viocin,Viomicin,Viomycins

Related Publications

F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
[Studies on antituberculous activity of lividomycin in vitro].
October 1971, Kekkaku : [Tuberculosis],
F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
[The experimental studies on antituberculous activity of lividomycin].
May 1972, Kekkaku : [Tuberculosis],
F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
The fundamental studies on antituberculous activities of lividomycin.
July 1971, Kekkaku : [Tuberculosis],
F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
[Lividomycin: microbiological activity in vitro and in vivo].
January 1973, Annali Sclavo; rivista di microbiologia e di immunologia,
F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
[In vitro antituberculous activity of levofloxacin].
June 1994, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
[In-vitro antibacterial activity of an aminoglucoside antibiotic: lividomycin A].
January 1975, Archivio Monaldi per la tisiologia e le malattie dell'apparato respiratorio,
F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
[Antituberculous in vitro activity of Helichrýsum arenárium extract].
January 2015, Eksperimental'naia i klinicheskaia farmakologiia,
F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
[Antituberculous action of a new antibiotic, Lividomycin. Effect on experimental tuberculosis of mice and cross resistance with other antituberculous agents].
August 1970, Kekkaku : [Tuberculosis],
F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
The reversal of the activity of antituberculous compounds in vitro.
August 1952, American review of tuberculosis,
F Kobayashi, and T Nagoya, and J Eda, and Y Yoshimura
[The study of the in vitro antituberculous activity of capreomycin].
September 1968, Antibiotica,
Copied contents to your clipboard!